Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Bachem is a Swiss-based contract development and manufacturing organization (CDMO) specializing in peptide-based active pharmaceutical ingredients (APIs) and complex organic molecules for pharmaceutical and biotech clients. The company operates production facilities in Switzerland (Bubendorf) and the US (Vista, California), serving the growing GLP-1 agonist market and other peptide therapeutics. With 30%+ gross margins and minimal debt, Bachem benefits from long-term supply agreements with major pharma companies developing peptide-based drugs.
Bachem generates revenue through long-term supply contracts with pharmaceutical companies requiring peptide APIs for drug manufacturing. The business model relies on technical expertise in solid-phase peptide synthesis (SPPS) and liquid-phase synthesis, creating high switching costs once a drug reaches clinical trials or commercialization due to regulatory validation requirements. Pricing power stems from the complexity of peptide manufacturing, stringent quality requirements (FDA/EMA compliance), and capacity constraints industry-wide. The company captures value through multi-year agreements with volume commitments and price escalation clauses tied to production scale.
GLP-1 agonist market growth and capacity allocation announcements (Novo Nordisk Wegovy/Ozempic, Eli Lilly Mounjaro supply chain)
New long-term supply agreement wins with pharmaceutical companies for peptide APIs
Capacity utilization rates at Bubendorf and Vista facilities, particularly for commercial-scale production
Regulatory approvals for client drugs requiring Bachem-manufactured APIs
Gross margin trajectory as new capacity comes online and fixed cost absorption improves
Technological shift toward recombinant protein production or mRNA-based therapies could reduce long-term peptide API demand, though peptides remain advantageous for certain therapeutic applications
Regulatory changes in pharmaceutical manufacturing standards (FDA/EMA) requiring facility upgrades or process revalidation could impose unexpected capex burdens
Biosimilar competition for established peptide drugs may pressure pricing on mature API contracts as patents expire
Chinese CDMO competitors (WuXi, Asymchem) expanding peptide capabilities with lower cost structures, though regulatory barriers and quality concerns provide some protection
Large pharmaceutical companies potentially insourcing peptide manufacturing to reduce supply chain dependence, particularly for blockbuster drugs
Capacity additions by competitors (Lonza, Cambrex) in peptide synthesis could create oversupply and pricing pressure post-2027
Negative free cash flow (-$100M TTM) due to heavy capex creates near-term cash burn, though 0.04x leverage and strong operating cash flow ($100M) provide cushion
Capex overruns or delays in new facility commissioning could extend the period of negative FCF and pressure liquidity if not offset by operating improvements
low - Pharmaceutical API demand is largely non-cyclical as prescription drug usage remains stable through economic cycles. However, biotech funding conditions affect clinical-stage development work (~25-30% of revenue). Commercial API production for approved drugs provides revenue stability regardless of GDP growth.
Rising rates have moderate indirect impact through two channels: (1) biotech client funding becomes more expensive, potentially delaying clinical programs and reducing development-stage API orders, and (2) valuation multiple compression for high-growth specialty chemical companies as discount rates increase. Direct impact is minimal given 0.04x debt/equity ratio and strong balance sheet. The company's heavy capex program ($300M) is largely self-funded, limiting financing cost sensitivity.
minimal - Bachem's client base consists primarily of investment-grade pharmaceutical companies (Novo Nordisk, Eli Lilly, others) with strong credit profiles. Payment terms are standard 30-60 days, and the company maintains a 2.44x current ratio, indicating no working capital stress. Biotech clients in development stage carry higher credit risk but represent smaller contract values.
growth - The stock attracts investors seeking exposure to the structural growth in peptide therapeutics, particularly GLP-1 obesity/diabetes drugs. The 7.3x P/S and 26.1x EV/EBITDA multiples reflect growth expectations rather than current profitability. Negative FCF and heavy capex phase appeal to investors with 3-5 year horizons willing to accept near-term dilution for long-term market share gains. The company's niche specialization and technical moat attract quality-focused growth investors rather than momentum traders.
moderate-to-high - As a mid-cap specialty chemical company with concentrated exposure to pharmaceutical end-markets, the stock exhibits above-average volatility. Single client contract wins/losses can move revenue materially given $600M revenue base. Limited liquidity in US OTC markets (BCHMF) versus primary Swiss listing increases bid-ask spreads. Recent 6.9% decline over 3 months reflects concerns about capex cycle and margin compression.
